Topics

PubMed Journals Articles About "Aurinia Drug Treat Autoimmune Kidney Disease Hits Goals" RSS

18:52 EST 23rd February 2020 | BioPortfolio

Aurinia Drug Treat Autoimmune Kidney Disease Hits Goals PubMed articles on BioPortfolio. Our PubMed references draw on over 21 million records from the medical literature. Here you can see the latest Aurinia Drug Treat Autoimmune Kidney Disease Hits Goals articles that have been published worldwide.

More Information about "Aurinia Drug Treat Autoimmune Kidney Disease Hits Goals" on BioPortfolio

We have published hundreds of Aurinia Drug Treat Autoimmune Kidney Disease Hits Goals news stories on BioPortfolio along with dozens of Aurinia Drug Treat Autoimmune Kidney Disease Hits Goals Clinical Trials and PubMed Articles about Aurinia Drug Treat Autoimmune Kidney Disease Hits Goals for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Aurinia Drug Treat Autoimmune Kidney Disease Hits Goals Companies in our database. You can also find out about relevant Aurinia Drug Treat Autoimmune Kidney Disease Hits Goals Drugs and Medications on this site too.

Showing "Aurinia drug treat autoimmune kidney disease hits goals" PubMed Articles 1–25 of 35,000+

Notopterygium incisum extract (NRE) rescues cognitive deficits in APP/PS1 Alzhneimer's disease mice by attenuating amyloid-beta, tau, and neuroinflammation pathology.

Alzheimer's disease (AD) is a frequently occurring disease of the elderly, and "deficiency" is the root of AD. Most famous experts of traditional Chinese medicine believe that the disease is based on deficiency, and the deficiency of kidney essence is the basis. Notopterygium incisum (Qiang huo) is specialized in bladder and liver and kidney. Treatment of liver and kidney deficiency, language difficulty, mental coma. Qiang huo yu feng tang has been used to treat liver and kidney deficiency, unclear language...


Perspiration interventions for conservative management of kidney disease and uremia.

There has been an increasing interest in developing novel technologies to treat patients with chronic kidney disease as evidenced by KidneyX, the public-private partnership between government and industry. Perhaps a simple technology for treating kidney failure would be to utilize perspiration. It is a physiological process, and when used properly it might not be an unpleasant experience. This review will explore the current state of knowledge regarding perspiration therapy in the setting of far advanced ki...

Gene therapy research for kidney diseases.

A resurgence in the development of newer gene therapy systems has led to recent successes in the treatment of B-cell cancers, retinal degeneration and neuromuscular atrophy. Gene therapy offers the ability to treat the patient at the root cause of their malady by restoring normal gene function and arresting the pathological progression of their genetic disease. The current standard of care for most genetic diseases is based upon the symptomatic treatment using polypharmacy while minimizing any potential adv...


Th1 chemokines in autoimmune endocrine disorders.

The chemokine receptor (CXCR)3 and its chemokines CXCL10, CXCL9 and CXCL11 are implicated in the pathogenesis of autoimmune diseases. Here, we review these chemokines in "autoimmune thyroiditis" (AT), "Graves' disease" (GD), "thyroid eye disease (TED), "Type 1 diabetes" (T1D), "Addison's disease" (AAD).

Chronic kidney disease and kidney stones.

Both chronic kidney disease (CKD) and kidney stones are major public health problems, which are closely interrelated. Recurrent kidney stones predispose to CKD although CKD seems to decrease risk of further kidney stone formation. Herein, we review new information of this interrelationship.

Autoimmune Gastritis.

Autoimmune gastritis (AG) is a corpus-restricted chronic atrophic gastritis associated with intrinsic factor deficiency, either with or without pernicious anemia. Autoimmune gastritis is a microscopic disease because patients present with no or vague symptoms, and clinicians rarely find endoscopic changes. Autoimmune gastritis only becomes a clinical disease when pathologists diagnose it in gastric biopsies performed for a variety of clinical indications. Unfamiliarity with this disease can result in misdia...

A treat-to-target approach for gout confers renoprotective effect in patients with chronic kidney disease stage 3.

The aim of this study was to assess changes in the estimated glomerular filtration rate (eGFR) in gouty patients with chronic kidney disease (CKD) using a "treat-to-target" (T2T) approach in gout. This multicenter observational retrospective study included patients diagnosed with gout and CKD stage 3 taking xanthine oxidase inhibitors (XOIs) (allopurinol or febuxostat) for at least 12 months. All patients were treated using a T2T strategy according to national gout guidelines to achieve the target levels o...

Living Kidney Donation in a Type 1 Dent's Disease Patient from His Mother.

Dent's disease is a rare X-linked recessive disorder that manifests in childhood or early adulthood and can lead to end-stage renal disease (ESRD). It occurs in males, who are hemizygous. In patients who develop ESRD, a deceased donor kidney transplant cures the disease. Females are obligate carriers of the mutated gene, and some show a mild Dent's disease phenotype. There may be reason for concern when considering a female obligate carrier (i.e., the mother) for kidney donation because of the risk of kidne...

Chronic Kidney Disease Diagnosis and Management: A Review.

Chronic kidney disease (CKD) is the 16th leading cause of years of life lost worldwide. Appropriate screening, diagnosis, and management by primary care clinicians are necessary to prevent adverse CKD-associated outcomes, including cardiovascular disease, end-stage kidney disease, and death.

Utilization of antihypertensive drugs among chronic kidney disease patients: Results from the Chinese cohort study of chronic kidney disease (C-STRIDE).

The utilization of antihypertensive drugs plays an important role in blood pressure control among chronic kidney disease (CKD) patients. Limited information was available on how antihypertensive drugs were used among Chinese CKD patients. In the present study, the utilization of antihypertensive drugs among a subgroup of hypertensive participants with a complete record of antihypertensive drug information from the Chinese Cohort Study of Chronic Kidney Disease was analyzed. Among 2213 subjects, 61.7% and 26...

Risk of progression of interstitial pneumonia with autoimmune features to a systemic autoimmune rheumatic disease.

The aim of this study was to determine the risk of developing a systemic autoimmune rheumatic disease (ARD) after an initial diagnosis of interstitial pneumonia with autoimmune features (IPAF).

Gap analysis for drug development policy-making: An attempt to close the gap between policy and its implementation.

Most drug development policies in developing countries are enacted without achieving the desired results. This study aims to determine the prioritization of drug development in Indonesia through the evidence-based policymaking process in order to close the distance between stated policy goals and the realization of planned goals.

Stent selection among patients with chronic kidney disease: Results from the NCDR CathPCI Registry.

This study sought to define contemporary rates of drug eluting stent (DES) usage in patients with chronic kidney disease (CKD).

Flow stimulates drug transport in a human kidney proximal tubule-on-a-chip independent of primary cilia.

Kidney disease modeling and assessment of drug-induced kidney injury can be advanced using three-dimensional (3D) microfluidic models that recapitulate in vivo characteristics. Fluid shear stress (FSS) has been depicted as main modulator improving in vitro physiology in proximal tubule epithelial cells (PTECs). We aimed to elucidate the role of FSS and primary cilia on transport activity and morphology in PTECs.

Hepatitis C in Chronic Kidney Disease - An Overview of the KDIGO Guideline.

Hepatitis C viral (HCV) infection is a global health problem with significant health and economic burden, which can lead to chronic kidney disease (CKD) and affect multiple organ systems. In addition, prevalence of hepatitis C remains higher in patients with CKD, including those on chronic hemodialysis and in individuals with a kidney transplant than in the general population. There has been a dramatic shift in the management of hepatitis C since Kidney Disease: Improving Global Outcome (KDIGO) published it...

Can naturally occurring nanoparticle-based targeted drug delivery effectively treat inflammatory bowel disease?

Decreased microcirculatory function measured by perfusion index is a novel indicator of diabetic kidney disease in patients with type 2 diabetes.

Diabetic kidney disease has been considered as an important risk factor of cardiovascular disease. Chronic hypoxia is considered to be the main cause of renal injury. Diminished microcirculatory blood flow could be associated with hypoxia in the kidney. Whether diminished microcirculation is associated with diabetic kidney disease has not yet been reported. Here, we investigated the correlation between microcirculatory function and diabetic kidney disease in patients with type 2 diabetes.

Therapy of diabetes mellitus in patients with chronic kidney disease.

Chronic kidney disease (CKD) is a common complication of diabetes mellitus and besides vascular nephropathy the most common cause of kidney failure (CKD G5). Along with an increase of the prevalence of diabetes the number of patients with diabetes and CKD will rise. General knowledge of the interactions between diabetes and CKD are essential for a safe and effective therapy. Appropriate glycemic control in patients with diabetes is important to prevent progression of CKD and hereby improve cardiovascular co...

Patterns of medication use and the burden of polypharmacy in patients with chronic kidney disease: the German Chronic Kidney Disease study.

Patients with chronic kidney disease (CKD) bear a substantial burden of comorbidities leading to the prescription of multiple drugs and a risk of polypharmacy. However, data on medication use in this population are scarce.

Treatment of chronic hepatitis C in patients with chronic kidney disease with Sofosbuvir-basead regimes.

To analyze the effectiveness and the safety of Sofosbuvir-based regimens to treat patients with chronic hepatitis C virus (HCV) infection and chronic kidney disease (CKD).

Modulation of polycystic kidney disease by non-coding RNAs.

microRNAs (miRNAs) are a class of small, evolutionarily conserved, non-coding RNAs (ncRNAs) that function as inhibitors of post-transcriptional mRNA expression. They are implicated in the pathogenesis of numerous diseases, including many common kidney conditions. In this review, we focus on how miRNAs impact autosomal dominant polycystic kidney disease (ADPKD) progression. We also discuss the feasibility of the emerging novel antisense oligonucleotides (ASOs) drug class, which includes anti-miRNA drugs, for...

Autoimmune polyglandular syndrome type III associated with antineutrophil cytoplasmic autoantibody-mediated crescentic glomerulonephritis: A case report and literature review.

Polyglandular autoimmune syndromes (PAS) are a heterogeneous group of rare diseases characterized by the association of at least 2 organ-specific autoimmune disorders, concerning both the endocrine and nonendocrine organs. Type III is defined as the combination of autoimmune thyroid disease and other autoimmune conditions (other than Addison disease), and is divided into 4 subtypes. We describe a patient with Hashimoto thyroiditis, adult-onset Still disease, alopecia, vasculitis, antineutrophil cytoplasmic ...

Effects of antihypertensives, lipid-modifying drugs, glycaemic control drugs and sodium bicarbonate on the progression of stages 3 and 4 chronic kidney disease in adults: a systematic review and meta-analysis.

To evaluate the effects of drug interventions that may modify the progression of chronic kidney disease (CKD) in adults with CKD stages 3 and 4.

Metformin Lactic Acidosis: should we still be afraid?

Metformin, the first choice drug for type 2 diabetes treatment in all stages of therapy, and one of the most widely prescribed anti-hyperglycemic agent worldwide, represents a rare example of an old drug which continues to display new beneficial effects in various fields. However, lactic acidosis (LA) persists as a serious adverse effect. LA incidence is low and is not necessarily determined by the administration of metformin. Unfortunately, the concern for this complication has negatively affected the drug...

Design and Baseline Characteristics of the Finerenone in Reducing Cardiovascular Mortality and Morbidity in Diabetic Kidney Disease Trial.

Among people with diabetes, those with kidney disease have exceptionally high rates of cardiovascular (CV) morbidity and mortality and progression of their underlying kidney disease. Finerenone is a novel, nonsteroidal, selective mineralocorticoid receptor antagonist that has shown to reduce albuminuria in type 2 diabetes (T2D) patients with chronic kidney disease (CKD) while revealing only a low risk of hyperkalemia. However, the effect of finerenone on CV and renal outcomes has not yet been investigated i...


Quick Search